High-Throughput Screening for the Potential Inhibitors of SARS-CoV-2 with Essential Dynamic Behavior
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Global health security has been challenged by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic. Due to the lengthy process of generating vaccinations, it is vital to reposition currently available drugs in order to relieve anti-epidemic tensions and accelerate the development of therapies for Coronavirus Disease 2019 (COVID-19), the public threat caused by SARS-CoV-2. High throughput screening techniques have established their roles in the evaluation of already available medications and the search for novel potential agents with desirable chemical space and more cost-effectiveness. Here, we present the architectural aspects of highthroughput screening for SARS-CoV-2 inhibitors, especially three generations of virtual screening methodologies with structural dynamics: ligand-based screening, receptor-based screening, and machine learning (ML)-based scoring functions (SFs). By outlining the benefits and drawbacks, we hope that researchers will be motivated to adopt these methods in the development of novel anti- SARS-CoV-2 agents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Current drug targets - 24(2023), 6 vom: 01., Seite 532-545 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Zhiwei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
High-throughput screening |
|---|
| Anmerkungen: |
Date Completed 19.06.2023 Date Revised 16.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1389450124666230306141725 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353826979 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353826979 | ||
| 003 | DE-627 | ||
| 005 | 20231226060915.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389450124666230306141725 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353826979 | ||
| 035 | |a (NLM)36876836 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Zhiwei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High-Throughput Screening for the Potential Inhibitors of SARS-CoV-2 with Essential Dynamic Behavior |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.06.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Global health security has been challenged by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic. Due to the lengthy process of generating vaccinations, it is vital to reposition currently available drugs in order to relieve anti-epidemic tensions and accelerate the development of therapies for Coronavirus Disease 2019 (COVID-19), the public threat caused by SARS-CoV-2. High throughput screening techniques have established their roles in the evaluation of already available medications and the search for novel potential agents with desirable chemical space and more cost-effectiveness. Here, we present the architectural aspects of highthroughput screening for SARS-CoV-2 inhibitors, especially three generations of virtual screening methodologies with structural dynamics: ligand-based screening, receptor-based screening, and machine learning (ML)-based scoring functions (SFs). By outlining the benefits and drawbacks, we hope that researchers will be motivated to adopt these methods in the development of novel anti- SARS-CoV-2 agents | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a High-throughput screening | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a ligand-based screening | |
| 650 | 4 | |a machine learning-based scoring functions | |
| 650 | 4 | |a receptor-based screening | |
| 650 | 4 | |a structural dynamics | |
| 650 | 7 | |a Protease Inhibitors |2 NLM | |
| 700 | 1 | |a Cai, Xinhui |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Qiushi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yizhen |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xuhua |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shengli |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug targets |d 2000 |g 24(2023), 6 vom: 01., Seite 532-545 |w (DE-627)NLM113669291 |x 1873-5592 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:6 |g day:01 |g pages:532-545 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389450124666230306141725 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 6 |b 01 |h 532-545 | ||